NYSE · ANVS
Annovis Bio, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ANVS: Nov 11, 2026
Annovis Bio, Inc. Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.3. The reported EPS for the same quarter last year was $-0.37.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.30 | $-0.30 | $-0.30 | 1 |
| Dec 2026 | $-0.17 | $-0.17 | $-0.17 | 1 |
| Mar 2027 | $-0.16 | $-0.16 | $-0.16 | 1 |
| Jun 2027 | $-0.13 | $-0.13 | $-0.13 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Fintel · Zacks · MarketBeat- RTTNews · Sep 25, 10:53 AM EDTWeekly Buzz: MESO, LLY, ANIP Win FDA Nod; KALA, HCTI Sign LOI; IMVT Halts Lupus Study(RTTNews) – Biotech and pharma companies delivered a busy slate of updates, spanning regulatory approvals, multibillion-dollar drug discovery partnerships and pivotal clinical-trial readouts across oncology, metabolic diseases, immunology and rare diseases.
- RTTNews · Sep 23, 9:34 AM EDTAnnovis Collaborates With Weave Bio On AI Use In NDA Submission For Butanetap(RTTNews) – Annovis Bio Inc. (ANVS), a clinical-stage biotechnology company, on Wednesday announced a partnership with Weave Bio to advance its lead candidate Butanetap toward a New Drug Application (NDA).
- Fintel · Sep 14, 9:07 PM EDTAnnovis Bio Consensus Price Target Lowered by 16.67% to $10.71The average one-year price target for Annovis Bio (NYSE:ANVS) has been revised to $10.71 / share as of September 11, 2026. This is a decrease of 16.67% from the prior estimate of $12.85 dated August 25, 2026. These figures represent aggregate analyst targets and do not constitute
- Zacks · Sep 8, 9:35 AM EDTAnnovis Bio (ANVS) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerAnnovis Bio (ANVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- MarketBeat · Sep 2, 10:01 PM EDTAnnovis Bio Targets March 2027 Alzheimer’s Readout, Prepares Rolling NDAAnnovis Bio (NYSE:ANVS) said it expects to report top-line results from the six-month portion of its pivotal Phase III Alzheimer’s disease trial in March 2027, while preparing a rolling new drug application, or NDA, that management said could begin in May if the study meets its e
- RTTNews · Jul 8, 10:41 AM EDTAnnovis Bio Jumps On Full Enrollment In Pivotal Phase 3 Alzheimer's Trial Of Buntanetap(RTTNews) – Annovis Bio, Inc.(ANVS), a clinical-stage biotechnology company, announced full enrollment of its pivotal Phase 3 trial evaluating Buntanetap in patients with early Alzheimer's disease or AD.
- RTTNews · May 27, 1:43 AM EDTAnnovis Bio Regains NYSE Compliance Ahead Of 18-Month Cure Period(RTTNews) – Annovis Bio, Inc. (ANVS), a clinical-stage biotechnology company, on Tuesday announced that it regained compliance with the New York Stock Exchange (NYSE) continued listing standards. Notably, the firm has regained full compliance within about 12 months, ahead of the
- RTTNews · May 21, 4:04 AM EDTAnnovis Announces Pricing Of $15 Mln Public Offering(RTTNews) – Annovis Bio Inc. (ANVS), a clinical-stage biotechnology company, on Wednesday announced the pricing of an underwritten public offering.
- RTTNews · May 20, 5:28 AM EDTAnnovis Bio Announces Offering Of Shares And Warrants To Advance Buntanetap In AD; Stock Down(RTTNews) – Annovis Bio, Inc. (ANVS), a clinical-stage biotechnology firm that develops drugs to treat neurodegeneration, announces a public offering in which it intends to offer shares and accompanying warrants.
- Fintel · Apr 9, 10:27 AM EDTAnnovis Bio (ANVS) Price Target Increased by 13.94% to 15.98The average one-year price target for Annovis Bio (NYSE:ANVS) has been revised to $15.98 / share. This is an increase of 13.94% from the prior estimate of $14.02 dated March 25, 2026. The price target is an average of many targets provided by analysts. The lat
- RTTNews · Apr 9, 9:01 AM EDTAnnoivs Bio Launches $10M Underwritten Offering(RTTNews) – Annovis Bio, Inc. (ANVS) announced a $10 million underwritten public offering of common stock and accompanying warrants. The offering is expected to provide additional capital to support the company's ongoing clinical programs in neurodegenerative diseases, including
- BNK Invest · Apr 6, 12:37 PM EDTMonday 4/6 Insider Buying Report: ANVS, VALEAs the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy — they expect to make money. So let's look at two noteworthy recent insider buys. At Annovis Bio, a filing with the SEC revealed that on Thursday, Director Michael B
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Annovis Bio, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.